北京时间2025年01月15日04时07分,Terns Pharmaceuticals, Inc.(TERN.us)股票出现异动,股价急速下跌5.00%。截至发稿,该股报4.56美元/股,成交量80.7751万股,换手率0.95%,振幅6.77%。
最近的财报数据显示,该股实现营业收入0.00美元,净利润-21.95百万美元,每股收益-0.28美元,毛利-206000.00美元,市盈率-3.88倍。
机构评级方面,在所有8家参与评级的机构中,75%的券商给予买入建议,25%的券商给予持有建议,无券商给予卖出建议。
Terns Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为1.26%。其相关个股中,Eterna Therapeutics Inc.、Jasper Therapeutics Inc C/Wts 24/09/2026 (To Pur Com)、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 (To Pur Com)涨幅较大,Eterna Therapeutics Inc.、Phio Pharmaceuticals Corp.、Soligenix, Inc.较为活跃,换手率分别为1083.36%、603.40%、421.59%,振幅较大的相关个股有Eterna Therapeutics Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 (To Pur Com)、Matinas Biopharma Holdings, Inc.,振幅分别为170.74%、146.24%、69.81%。
Terns Pharmaceuticals, Inc.公司简介:Terns Pharmaceuticals Inc是一家临床阶段的生物制药公司。它正在开发一个小分子单一药物和联合疗法候选药物,用于治疗非酒精性脂肪性肝炎(NASH)和其他慢性肝病。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.